At a glance
ClinicalIndex Comparison RecordN/ACompleted· 118 enrolled
Drug / intervention
topical tetracaine hydrochloride 1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Short Term Topical Tetracaine is Safe and Highly Efficacious for the Treatment of Pain Caused by Corneal Abrasions: a Double-blind Randomized Clinical Trial
In Brief
A clinical study evaluating topical tetracaine hydrochloride 1% and Placebo for Corneal Abrasion. Completed, enrolled 118 participants.
Detailed Summary
The objective of this study was to show that patients with corneal abrasions would experience more pain relief with short term topical tetracaine than placebo, have similar complication rates, and take less hydrocodone for breakthrough pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Abrasion
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
Primary CompletionSep 2017
Study CompletionSep 2018
First PostedDec 2019
TodayJul 2026
First PostedDec 5, 2019
Enrollment StartJan 1, 2015
Primary CompletionSep 30, 2017
Study CompletionSep 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.6 years ago
Interventions
topical tetracaine hydrochloride 1%drug
topical ophthalmologic anesthestic
Placebodrug
Placebo